Shares of Danish pharmaceutical company Novo Nordisk plunged by 12 percent after disappointing trial results revealed that its weight-loss drug, semaglutide, did not slow the progression of Alzheimer\u2019s disease. The company’s value has now reached its lowest point in four years.<\/p>\n
Novo Nordisk had been exploring the potential of semaglutide, the active ingredient in its popular weight-loss medications Wegovy and Ozempic, as a treatment for patients with mild cognitive impairment or mild dementia due to Alzheimer\u2019s disease. Early indicators had sparked optimism, but the large-scale clinical trials did not deliver the hoped-for results.<\/p>\n
The company tested semaglutide in two major studies involving 3,808 participants aged 55 to 85. Half of the participants received the drug in its oral form, while the other half took a placebo. However, the results showed that semaglutide did not significantly reduce the progression of Alzheimer\u2019s compared to the placebo.<\/p>\n
"Based on the significant unmet need in Alzheimer\u2019s disease as well as a number of indicative data points, we felt we had a responsibility to explore semaglutide\u2019s potential, despite a low likelihood of success", said Martin Holst Lange, Novo Nordisk\u2019s chief scientific officer and executive vice president of research and development. "While semaglutide did not demonstrate efficacy in slowing the progression of Alzheimer\u2019s disease, the extensive body of evidence supporting semaglutide continues to provide benefits for individuals with type 2 diabetes, obesity, and related comorbidities."<\/p>\n
The trial\u2019s outcome was met with disappointment by experts and advocates within the Alzheimer\u2019s research community. Fiona Carragher, chief policy and research officer at Alzheimer\u2019s Society, expressed regret over the findings but emphasized the broader value of clinical trials.<\/p>\n
"It\u2019s very disappointing that these eagerly awaited results are not what we hoped for", Carragher said. "However, no trial is wasted. Every investigation helps us develop better drugs and design better trials in the future. Research is hope, and there are currently over 130 Alzheimer\u2019s drugs in clinical trials, of which around 30 are in late-stage trials, the final step before they are considered by regulators."<\/p>\n
Carragher also stressed the importance of early diagnosis as new treatments continue to be developed. "Despite these results, there is a critical window of opportunity to prepare for other disease-modifying treatments coming down the track. The Government must invest in getting more people diagnosed at an earlier stage, as one in three people with dementia don\u2019t currently have a diagnosis. We must avoid a situation where regulators approve treatments but too many people don\u2019t receive them because they don\u2019t have an early and accurate diagnosis."<\/p>\n
Dr. Susan Kohlhaas, executive director of research at Alzheimer\u2019s Research UK, echoed the sense of disappointment but also highlighted the complexity of tackling Alzheimer\u2019s disease.<\/p>\n
"Today\u2019s disappointing results on semaglutide will come as a blow for people affected by Alzheimer\u2019s", she said. "These trial results are another reminder that Alzheimer\u2019s is driven by several different biological processes. No single approach is likely to be enough. The field now needs to focus on understanding those processes in much greater detail and developing treatments that can be used together to tackle the disease from multiple angles."<\/p>\n
Despite the setback, Novo Nordisk emphasized that the extensive body of evidence supporting semaglutide continues to demonstrate its effectiveness in treating type 2 diabetes and obesity. Meanwhile, Alzheimer\u2019s researchers remain committed to exploring new avenues for developing treatments for the neurodegenerative condition, with many other drugs currently in the pipeline.<\/p>\n
As the global pharmaceutical industry races to address Alzheimer\u2019s disease, this latest development is a stark reminder of the complexities involved in tackling such a multifaceted condition.<\/p>\n
Read the source<\/em><\/p>\n